ECFS 2020 - Optimizing pharmaceutical care in cystic fibrosis

284    www.ecfs.eu OPTIMIZING PHARMACEUTICAL CARE IN CYSTIC FIBROSIS PATIENT REGISTRIES IN PHARMACOVIGILANCE CHAPTER 16 [6] Pharmacovigilance. ENoCfPa. The European Union electronic Register of Post-Authorisation Studies (EU PAS Register). n.d. [Available from: http://www. encepp.eu/encepp_studies/ indexRegister.shtml . [7] Bouvy JC, Blake K, Slattery J, De Bruin ML, Arlett P, Kurz X. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013. Pharmacoepidemiol Drug Saf. 2017;26(12):1442-50. [8] Olmo CA, McGettigan P, Kurz X. Barriers and Opportunities for Use of Patient Registries in Medi- cines Regulation. Clin Pharmacol Ther. 2019;106(1):39-42. [9] European Medical Agency. Patient Registries Workshop, 28 October 2016. 2017. Avail- able from: https://www.ema. europa.eu/en/documents/report/ report-patient-registries-work- shop_en.pdf . [10] European Medical Agency. Report on Cystic Fibrosis Registries - Workshop 14 June 2017. 2017. Available from: https:// www.ema.europa.eu/en/docu- ments/report/report-cystic-fibro- sis-registries_en.pdf . References [1] European Medical Agency. Pharmaciovigilance overview. n.d. [Available from: https://www. ema.europa.eu/en/human-reg- ulatory/overview/pharmacovigi- lance-overview . [2] European Medical Agency. Good pharmacovigilance practices. n.d. [Available from: https://www. ema.europa.eu/en/human-regu- latory/post-authorisation/pharma- covigilance/good-pharmacovigi- lance-practices . [3] Arlett P, Portier G, de Lisa R, Blake K, Wathion N, Dogne JM, et al. Proactively managing the risk of marketed drugs: expe- rience with the EMA Pharma- covigilance Risk Assessment Committee. Nat Rev Drug Discov. 2014;13(5):395-7. [4] Postigo R, Brosch S, Slattery J, van Haren A, Dogne JM, Kurz X, et al. EudraVigilance Medi- cines Safety Database: Publicly Accessible Data for Research and Public Health Protection. Drug Saf. 2018;41(7):665-75. [5] European Medical Agency. Post-authorisation safety studies (PASS). n.d. [Available from: https://www.ema.europa.eu/ en/human-regulatory/post-au- thorisation/pharmacovigilance/ post-authorisation-safety-stud- ies-pass-0 .

RkJQdWJsaXNoZXIy Mzc2ODc=